1-3 of 3
Linda Wu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib

Ryan Jacobs, Xiaoxiao Lu, Bruno Emond, Laura Morrison, Frédéric Kinkead, Patrick Lefebvre, Marie-Hélène Lafeuille, Wasiulla Khan, Linda Wu, Zaina P. Qureshi, Moshe Yair Levy
Journal: Blood
Blood (2022) 140 (Supplement 1): 1931–1933.
https://doi.org/10.1182/blood-2022-163387
Published: 2022
Journal Articles

Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib

Ryan Jacobs, Ruibin Wang, Jinghua He, Xiaoxiao Lu, Linda Wu, Wasiulla Khan, Zaina P. Qureshi, Moshe Yair Levy
Journal: Blood
Blood (2022) 140 (Supplement 1): 8017–8018.
https://doi.org/10.1182/blood-2022-168081
Published: 2022
Journal Articles

Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry

Nilanjan Ghosh, Jeff P. Sharman, Jacqueline C. Barrientos, Danielle Brander, Meghan Gutierrez, Linda Wu, Zaina P. Qureshi, Sandhya Upasani, Maoko Naganuma, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 7047–7049.
https://doi.org/10.1182/blood-2022-155649
Published: 2022